Mizuho Securities Maintains Axsome Therapeutics(AXSM.US) With Buy Rating
Morgan Stanley Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $115
Wells Fargo Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $140
Strong Commercial Performance and Growth Potential Drive Buy Rating for Axsome Therapeutics' Auvelity
Morgan Stanley Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $115
Mizuho Securities Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Announces Target Price $106
Axsome Therapeutics Is Maintained at Outperform by RBC Capital
Axsome Therapeutics Analyst Ratings
RBC Lifts Price Target on Axsome Therapeutics to $131 From $130, Keeps Outperform Rating
Wells Fargo Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $140
Buy Rating Justified for Axsome Therapeutics Amidst Strong Market Opportunities and Promising Trial Outcomes
Mizuho Securities Maintains Axsome Therapeutics(AXSM.US) With Buy Rating
Analysts Offer Insights on Healthcare Companies: Establishment Labs Holdings (ESTA), Alkermes (ALKS) and Axsome Therapeutics (AXSM)
Mizuho Securities Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $106
RBC Capital Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $130
RBC Capital Sticks to Their Buy Rating for Axsome Therapeutics (AXSM)
TD Cowen Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $120
Morgan Stanley Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $115
Mizuho Securities Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $106
Axsome Therapeutics Analyst Ratings